Click any tag below to further narrow down your results
Links
This is the second part of an investigation into whether OpenEvidence, a medical AI company valued at $15B, has technology and content worth that price. The author finds the proprietary AI, content ownership, and accuracy claims all look weak under scrutiny.
- OpenEvidence doesn't own its content; publishers can pull their material at any time, which undercuts the moat a buyer would be paying for.
- Accuracy claims collapse outside exam settings: the company's near-perfect USMLE scores drop to about 27% on real-world clinical cases.
- Ad revenue projections ($400M to $500M in 2026) still put the $15B valuation at 30x to 37.5x a single year of sales, and the company's own CEO now pitches drug discovery as the real prize.
Anthropic has partnered with OpenEvidence, a medical AI company, to take its health-focused AI tools global. The deal follows Anthropic's recent build-out of a physical biology lab as it pushes into drug science.
- Anthropic and OpenEvidence are partnering to expand medical AI tools to markets worldwide.
- The move comes days after Reuters reported Anthropic had set up a lab for hands-on biology work tied to its drug science push.
- The article notes rising public and political unease about AI's reach, with some executives and lawmakers calling for a slowdown in development.
OpenEvidence is an AI search tool for doctors that indexes only peer-reviewed journals and clinical guidelines. Clinicians verify their credentials to access aggregated, real-time research from sources like JAMA and NEJM, cutting down on AI hallucinations. The free, ad-supported platform has just closed a $200 million Series C round at a $6 billion valuation.
- OpenEvidence raised $200M just three months after its $210M Series B, hitting a $6B valuation
- It's a credential-gated AI search tool for doctors that only pulls from peer-reviewed sources like JAMA, NEJM, PubMed, CDC and FDA to avoid hallucinations
- It's explicitly not for patients—designed to help doctors stay current on unfamiliar diseases, treatments, or new protocols
- The platform is free and ad-supported